Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MYGN

Myriad Genetics, Inc

Dec 13 • 04:00PM ET

14.43

Dollar change -0.07
Percentage change -0.48	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH INCY QGEN EXAS NTLA CRSP CDNA TXG TWST

| Held by: IJR VTI VB IWM VXF XBI VBR VBK IWN SPSM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.30	Insider Own	3.76%	Shs Outstand	91.00M	Perf Week	-4.63%
Market Cap	1.31B	Forward P/E	96.68	EPS next Y	0.15	Insider Trans	-3.04%	Shs Float	87.62M	Perf Month	-8.56%
Income	-116.00M	PEG	-	EPS next Q	0.03	Inst Own	100.22%	Short Float	3.87%	Perf Quarter	-48.28%
Sales	823.60M	P/S	1.59	EPS this Y	147.49%	Inst Trans	-1.59%	Short Ratio	3.97	Perf Half Y	-37.80%
Book/sh	8.04	P/B	1.79	EPS next Y	16.42%	ROA	-10.40%	Short Interest	3.39M	Perf Year	-30.89%
Cash/sh	1.10	P/C	13.09	EPS next 5Y	70.00%	ROE	-16.39%	52W Range	14.20 - 29.30	Perf YTD	-24.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-13.47%	52W High	-50.75%	Beta	1.88
Dividend TTM	-	Quick Ratio	1.73	Sales past 5Y	4.63%	Gross Margin	63.96%	52W Low	1.62%	ATR (14)	0.91
Dividend Ex-Date	-	Current Ratio	1.90	EPS Y/Y TTM	61.33%	Oper. Margin	-12.53%	RSI (14)	29.67	Volatility	6.15% 5.11%
Employees	2700	Debt/Eq	0.20	Sales Y/Y TTM	12.15%	Profit Margin	-14.08%	Recom	2.75	Target Price	21.62
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	67.52%	Payout	-	Rel Volume	1.34	Prev Close	14.50
Sales Surprise	1.21%	EPS Surprise	220.86%	Sales Q/Q	11.15%	Earnings	Nov 07 AMC	Avg Volume	854.96K	Price	14.43
SMA20	-7.05%	SMA50	-24.14%	SMA200	-37.06%	Trades		Volume	1,148,550	Change	-0.48%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Initiated	UBS	Neutral	$18
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$30 → $21
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight	$32
Aug-28-24	Initiated	Wells Fargo	Overweight	$35
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$29
Jun-03-24	Resumed	Jefferies	Underperform	$20
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform	$25 → $35
Dec-21-23	Resumed	Piper Sandler	Neutral	$23
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$20
Dec-14-23	Initiated	Guggenheim	Buy	$23
Dec-13-23	Initiated	Wolfe Research	Outperform	$28
Jul-05-23	Resumed	JP Morgan	Underweight	$18
May-23-23	Upgrade	Goldman	Sell → Buy	$18 → $25
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$25
Oct-06-22	Initiated	Stephens	Equal-Weight	$22
Oct-15-21	Resumed	Cowen	Market Perform	$33
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell	$25
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform	$30 → $28
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral	$45 → $40

Show Previous Ratings

Dec-10-24 06:26PM	Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing (GlobeNewswire) -5.41%
04:05PM	Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member (GlobeNewswire)
08:00AM	Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines (GlobeNewswire)
Dec-09-24 04:05PM	Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium (GlobeNewswire)
08:00AM	NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris Test as an 'Advanced Tool' Recommended for Prognostic Assessment (GlobeNewswire)
04:30PM	Loading…
Nov-20-24 04:30PM	Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 v2 (GlobeNewswire)
Nov-19-24 08:00AM	Myriad Genetics Announces Prequel Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy (GlobeNewswire)
07:27AM	Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley (TipRanks)
Nov-13-24 08:00AM	Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch (GlobeNewswire)
Nov-08-24 02:26AM	Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ... (GuruFocus.com)
Nov-07-24 06:30PM	Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics (Zacks)
06:00PM	Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
05:02PM	Myriad: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance (GlobeNewswire)
Nov-04-24 08:39AM	Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing (GlobeNewswire)
11:15AM	Loading…
Nov-02-24 11:15AM	Myriad weakness due to UnitedHealth coverage update, says Stephens (TipRanks)
Nov-01-24 06:55PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) -18.08%
Oct-30-24 08:00AM	Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-28-24 10:01AM	Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-24 02:19PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Oct-16-24 09:00AM	Myriad Genetics and jscreen Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access (GlobeNewswire)
Oct-15-24 09:00AM	Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration (GlobeNewswire)
Oct-09-24 07:49AM	Myriad signs five partnerships to study MRD testing in breast cancer (Clinical Trials Arena) -6.12%
Oct-08-24 04:05PM	Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer (GlobeNewswire)
Oct-04-24 06:33AM	Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests (Medical Device Network)
Oct-03-24 09:00AM	Myriad Genetics and Ultima Genomics to Explore the UG 100 Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics (GlobeNewswire)
Oct-01-24 04:05PM	Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date (GlobeNewswire)
Sep-25-24 06:38PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Sep-18-24 09:50AM	Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock (Zacks)
08:00AM	Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference (GlobeNewswire)
06:37PM	Loading…
Sep-16-24 06:37PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Sep-13-24 01:54AM	Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
01:54AM	Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Sep-10-24 01:17AM	Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Sep-05-24 11:31AM	Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound? (Zacks) +9.07%
08:00AM	Myriad Genetics to Host Investor Event on October 9, 2024 (GlobeNewswire)
01:33AM	Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Sep-04-24 06:50PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) -7.65%
Aug-30-24 09:50AM	Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-23-24 07:01PM	Insider Sale at Myriad Genetics Inc (MYGN): SVP, Chief of Staff Margaret Ancona Sells Shares (GuruFocus.com)
Aug-21-24 08:00AM	Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences (GlobeNewswire)
Aug-20-24 07:01PM	Insider Sale: Director Rashmi Kumar Sells 7,500 Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Aug-09-24 07:07PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Aug-08-24 08:16AM	Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised (Zacks)
Aug-07-24 10:36PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Aug-06-24 07:00PM	Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:30PM	Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
05:28PM	Myriad: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% (GlobeNewswire)
Aug-01-24 04:05PM	Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific (GlobeNewswire)
Jul-31-24 08:50AM	Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer (GlobeNewswire)
Jul-30-24 08:00AM	Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-17-24 08:00AM	What We Don't Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk (GlobeNewswire)
Jul-15-24 02:01PM	Myriad Genetics (MYGN) Expands in MRD Testing With New Collab (Zacks)
Jul-11-24 09:00AM	Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing (GlobeNewswire)
Jul-10-24 07:53AM	Myriad Genetics (MYGN) Advances in MRD Space With New Patent (Zacks)
Jul-09-24 09:00AM	Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date (GlobeNewswire)
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
Jul-03-24 07:07PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Jul-02-24 09:00AM	Myriad Genetics Earns 2024 Great Place To Work Certification (GlobeNewswire)
Jun-24-24 04:05PM	Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election (GlobeNewswire)
Jun-12-24 11:46AM	Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing (Zacks)
Jun-11-24 09:36AM	Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes (Zacks)
08:00AM	Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries (GlobeNewswire)
Jun-06-24 11:31AM	Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-05-24 02:35AM	Insider Sale: Director Daniel Spiegelman Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Jun-04-24 09:00AM	Myriad Genetics Launches New Universal Plus Panel for Foresight Carrier Screen (GlobeNewswire)
Jun-03-24 04:05PM	Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore as a Clinical Breast Cancer Risk Assessment Tool (GlobeNewswire)
May-30-24 05:55PM	QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications (GlobeNewswire)
May-23-24 06:44PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
06:00PM	Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO Annual Meeting (GlobeNewswire)
May-16-24 04:05PM	New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer (GlobeNewswire)
02:52AM	Insider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
02:52AM	Insider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
May-13-24 09:45AM	Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating (MT Newswires)
May-10-24 06:00AM	Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life (InvestorPlace)
May-09-24 06:55PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) +5.43%
May-08-24 04:28PM	Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript (Insider Monkey) +21.08%
03:59PM	Sector Update: Health Care Stocks Softer Late Afternoon (MT Newswires)
01:54PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
01:24PM	Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue (MT Newswires)
12:15PM	Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1 (Zacks)
03:47AM	Myriad Genetics Inc (MYGN) Q1 2024 Earnings Call Transcript Highlights: Strong Start with ... (GuruFocus.com)
May-07-24 09:56PM	MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00PM	Myriad (MYGN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
06:02PM	Myriad Genetics Reports Q1 2024 Earnings: Revenue Growth Surpasses Estimates Amidst Challenges (GuruFocus.com)
05:50PM	Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:47PM	Myriad: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA (GlobeNewswire)
09:00AM	Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business (GlobeNewswire)
Apr-30-24 04:05PM	Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-24-24 10:01AM	Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-17-24 08:00AM	Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor (GlobeNewswire)
Apr-16-24 09:15AM	New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen (GlobeNewswire)
Apr-11-24 10:00AM	Myriad Genetics (MYGN) Announces Favorable Research Results (Zacks)
Apr-09-24 09:10AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
08:00AM	Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing (GlobeNewswire)
Mar-28-24 11:30AM	Why Is Myriad (MYGN) Down 1% Since Last Earnings Report? (Zacks)
Mar-27-24 07:51AM	Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay (Zacks)
Mar-21-24 09:40PM	Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date (GlobeNewswire)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DIAZ PAUL J	President and CEO	Oct 11 '24	Sale	22.93	15,000	343,950	962,378	Oct 11 05:23 PM
DIAZ PAUL J	Officer	Oct 11 '24	Proposed Sale	22.93	15,000	343,950		Oct 11 10:35 AM
Ancona Margaret	Officer	Aug 21 '24	Proposed Sale	27.82	11,538	321,019		Sep 16 02:30 PM
DIAZ PAUL J	President and CEO	Sep 11 '24	Sale	26.72	15,000	400,800	977,378	Sep 12 04:11 PM
Muzzey Dale	Chief Scientific Officer	Sep 11 '24	Sale	26.17	2,100	54,961	108,013	Sep 12 04:09 PM
Muzzey Dale	Officer	Sep 11 '24	Proposed Sale	26.17	2,100	54,961		Sep 11 03:26 PM
DIAZ PAUL J	Officer	Sep 11 '24	Proposed Sale	26.72	15,000	400,800		Sep 11 10:05 AM
Dreismann Heinrich	Director	Sep 09 '24	Sale	27.05	10,000	270,520	121,648	Sep 09 05:48 PM
Dreismann Heinrich	Director	Sep 10 '24	Proposed Sale	27.00	10,000	270,000		Sep 09 02:52 PM
Reitan Colleen F	Director	Sep 03 '24	Sale	27.95	46,012	1,285,851	42,533	Sep 04 07:38 PM
Reitan Colleen F	Director	Sep 03 '24	Proposed Sale	28.19	46,012	1,297,078		Sep 03 10:11 AM
Ancona Margaret	SVP, Chief of Staff	Aug 21 '24	Sale	27.82	11,538	320,987	79,366	Aug 23 04:16 PM
Kumar Rashmi	Director	Aug 19 '24	Sale	28.01	7,500	210,075	77,392	Aug 20 04:38 PM
Kumar Rashmi	Director	Aug 19 '24	Proposed Sale	28.01	7,500	210,075		Aug 19 02:46 PM
SPIEGELMAN DANIEL K	Director	Jun 04 '24	Sale	22.05	3,788	83,525	32,917	Jun 04 05:57 PM
SPIEGELMAN DANIEL K	Director	Jun 03 '24	Sale	22.04	3,788	83,488	36,705	Jun 04 05:57 PM
DIAZ PAUL J	President and CEO	May 14 '24	Sale	25.21	95,000	2,394,798	1,141,166	May 15 05:49 PM
DIAZ PAUL J	President and CEO	May 15 '24	Sale	25.07	75,000	1,880,415	1,066,166	May 15 05:49 PM
DIAZ PAUL J	President and CEO	May 13 '24	Sale	25.13	57,844	1,453,550	1,236,166	May 15 05:49 PM
Newcomer Lee Nisley	Director	May 13 '24	Sale	25.30	6,200	156,860	66,650	May 15 05:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MYGN

Myriad Genetics, Inc

Upgrade your FINVIZ experience